A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Hao-Wen SimKerrie L McDonaldZarnie LwinElizabeth H BarnesMark RosenthalMatthew C FooteEng-Siew KohMichael BackHelen WheelerErik P SulmanMichael E BucklandLauren FisherRobyn LeonardMerryn HallDavid M AshleySonia YipJohn SimesMustafa KhasrawPublished in: Neuro-oncology (2021)
The veliparib-containing regimen was feasible and well tolerated. However, there was insufficient evidence of clinical benefit in this population. Further information from correlative translational work and other trials of PARP inhibitors in glioblastoma are still awaited.